Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin


28 November 2017

Cognition Kit wearable technology demonstrates high compliance among patients with major depressive disorder (MDD)

​At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.

The study was sponsored by Takeda Pharmaceuticals and used Cognition Kit™ technology, developed in a joint venture between Cambridge Cognition and Ctrl Group, to measure mood and cognition in real-world settings.

The benefits of collecting real-world evidence

Collecting data in normal, day-­to-­day circumstances is a growing trend in the healthcare industry. Pharmaceutical companies now aim to demonstrate evidence of successful real-world outcomes to differentiate their products in a competitive market while also satisfying the demands of payers and patients.

Real-world evidence can help improve health outcomes for patients, reduce medical costs and demonstrate the cost-effectiveness of a treatment. However, conducting studies outside of a clinical setting and gaining compliance from patients when unsupervised has to date been challenging.

In the reported study, thirty participants aged 18­ - 65 with a clinical diagnosis of mild to moderate depression who had been prescribed antidepressants took part over a 6­-week period, being assessed daily at regular intervals on the Apple Watch®.

How wearables can be used to reliably collect real-world evidence

The researchers found that patients were highly compliant with the wearable Cognition Kit technology on a daily basis to evaluate their mood (95 percent compliant) and cognitive health (96 percent compliant). The data collected with Cognition Kit shows how wearable technology can be used to collect real world evidence reliably - even in challenging patient groups - and how it may also aid communication between patients and clinicians, ensuring symptoms are detected early.

Dr. Francesca Cormack, Director of Research and Innovation, at Cambridge Cognition said: 

We are delighted by the study results. These findings demonstrate that high frequency, near­patient testing using Cognition Kit software on wearable devices is accurate and well­ tolerated by patients with excellent levels of compliance. This is of huge significance, demonstrating a feasible technology platform for enabling the pharmaceutical industry to collect real world evidence.

Nicole Mowad-­Nassar, Vice President, External Partnerships, at Takeda Pharmaceuticals U.S.A. said: "This initiative is an excellent example of the work being done at Takeda to build a body of evidence for new ways of measuring outcomes in mental health. Technology like Cognition Kit allows us to create real time objective measurements for assessing effects in depression that could transform patient care by increasing our ability to estimate clinical conditions and support earlier engagement between the patient and clinician. We are encouraged by the study results and look forward to learning more about the intersection of technology and healthcare."

Interested in learning more about Cognition Kit?

For more information about Cognition Kit and how it is taking research out of the lab and into daily life to enable doctors, scientists and the public to better understand and manage day-to-day brain health, please visit the Cognition Kit website or contact us directly.